Search Within

Yue Christine Lu

Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
Groups
  1. GME, Pediatrics (8)
  2. GSK Faculty (8)
  3. Graduate Medical Education (8)
  4. Department of Pathology and Laboratory Medicine (6)
  5. Sloan Kettering Institute Postdocs (5)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)

More Groups

People
  1. Dana Casey (4)
  2. Elisa De Stanchina (4)
  3. Jeremy Setton (4)
  4. Jorge Reis-Filho (4)
  5. Ken Pitter (4)
  6. Marc Ladanyi (4)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (1)
  5. 2018 (3)
Publications
  1. International Journal of Radiation Oncology, Biology, Physics (3)
  2. Clinical Cancer Research (1)
  3. JNCI: Journal of the National Cancer Institute (1)
  4. Journal of Thoracic Oncology (1)
  5. Nature Cancer (1)
  6. Pediatric Blood and Cancer (1)
Publishers
  1. Elsevier Inc. (4)
  2. American Association for Cancer Research (1)
  3. Nature Research (1)
  4. Oxford University Press (1)
  5. Wiley Periodicals, Inc (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • TA0953/HM06, a novel RET-specific inhibitor effective in extracranial and CNS disease models of NSCLC with RETfusions
    Meeting Abstract

    Odintsov, I.; Lui, A. J. W.; Delasos, L.; Khodos, I.; Chang, Q.; Mattar, M. S.; Vojnic, M.; Lu, Y. C.; Kunte, S.; Bonifacio, A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Targeting mTOR and MEK or ERK inhibits the growth of PDX models of NF1-deficient pediatric sarcoma
    Meeting Abstract

    Lu, Y. C.; Odintsov, I.; Khodos, I.; Mattar, M.; Glade Bender, J.; Wexler, L.; de Stanchina, E.; Ladanyi, M.; Somwar, R.
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy
    Journal Article

    Pitter, K. L.; Casey, D. L.; Lu, Y. C.; Hannum, M.; Zhang, Z.; Song, X.; Pecorari, I.; McMillan, B.; Ma, J.; Samstein, R. M.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions
    Journal Article

    Sato, H.; Schoenfeld, A. J.; Siau, E.; Lu, Y. C.; Tai, H.; Suzawa, K.; Kubota, D.; Lui, A. J. W.; Qeriqi, B.; Mattar, M.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Pathogenic mutations in ATM as determinants of local control in non-small cell lung cancers treated with radiation therapy
    Meeting Abstract

    Pitter, K. L.; Casey, D. L.; Setton, J.; Lu, C.; Rimner, A.; Reis-Filho, J.; Powell, S. N.; Lee, N.; Chan, T. A.; Riaz, N.
    International Journal of Radiation Oncology, Biology, Physics (2018)

    Fulltext@MSK | Save
  • Pathogenic mutations in ATM enhance radio-sensitivity and local control in patients with primary and metastatic breast cancer
    Meeting Abstract

    Casey, D. L.; Pitter, K. L.; Setton, J.; Braunstein, L. Z.; Robson, M. E.; Reis-Filho, J.; Weigelt, B.; Lu, C.; Powell, S. N.; Chan, T. A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2018)

    Fulltext@MSK | Save
  • Pathogenic mutations in ATM predict for enhanced local control in prostate cancers treated with radiation thearpy
    Meeting Abstract

    Lu, C.; Pitter, K. L.; Casey, D. L.; Riaz, N.; Lee, N.; McBride, S.; Reis-Filho, J.; Powell, S. N.; Zelefsky, M. J.; Chan, T. A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2018)

    Fulltext@MSK | Save